Effect of monoamine reuptake inhibitor NS 2330 in advanced Parkinson's disease

被引：37

作者：

Bara-Jimenez, W ^{[1
]}

Dimitrova, T ^{[1
]}

Sherzai, A ^{[1
]}

Favit, A ^{[1
]}

Mouradian, MM ^{[1
]}

Chase, TN ^{[1
]}

机构：

[1] NINDS, Expt Therapeut Branch, NIH, Bethesda, MD 20892 USA

来源：

MOVEMENT DISORDERS | 2004年 / 19卷 / 10期

关键词：

Parkinson's disease; dyskinesia; dopamine; levodopa; striatum; uptake; transporter; clinical trial;

D O I：

10.1002/mds.20124

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Dopamine reuptake blockers, by enhancing and stabilizing intrasynaptic transmitter levels, could help palliate motor dysfunction in Parkinson's disease. This randomized, double-blind, placebo-controlled study compared the acute effects of the monoamine uptake inhibitor NS 2330 to those of placebo in 9 relatively advanced parkinsonian patients. At the dose administered, no change in parkinsonian scores was found when NS 2330 was given alone or with levodopa. Moreover, NS 2330 coadministration did not appear to alter dyskinesia severity or the duration of the antiparkinsonian response to levodopa. The drug was well tolerated. Under the conditions of this study, the present results failed to support the usefulness of dopamine reuptake inhibition in the treatment of advanced Parkinson's disease.

引用

页码：1183 / 1186

页数：4

共 16 条

[1] EFFECTS OF L-DOPA ON EXTRACELLULAR DOPAMINE IN STRIATUM OF NORMAL AND 6-HYDROXYDOPAMINE-TREATED RATS [J].

ABERCROMBIE, ED ;

BONATZ, AE ;

ZIGMOND, MJ .

BRAIN RESEARCH, 1990, 525 (01) :36-44

[2] Adenosine A2A receptor antagonist treatment of Parkinson's disease [J].

Bara-Jimenez, W ;

Sherzai, A ;

Dimitrova, T ;

Favit, A ;

Bibbiani, F ;

Gillespie, M ;

Morris, MJ ;

Mouradian, MM ;

Chase, TN .

NEUROLOGY, 2003, 61 (03) :293-296

[3]

Chase TN, 2000, ANN NEUROL, V47, pS122

[4]

Cragg SJ, 2000, J NEUROSCI, V20, P8209

[5]

Cragg SJ, 2002, J NEUROSCI, V22, P5705

[6] Dopamine synthesis, uptake, metabolism, and receptors: Relevance to gene therapy of Parkinson's disease [J].

Elsworth, JD ;

Roth, RH .

EXPERIMENTAL NEUROLOGY, 1997, 144 (01) :4-9

[7] BUPROPION IN PARKINSONS-DISEASE [J].

GOETZ, CG ;

TANNER, CM ;

KLAWANS, HL .

NEUROLOGY, 1984, 34 (08) :1092-1094

[8] Dopamine, but not norepinephrine or serotonin, reuptake inhibition reverses motor deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates [J].

Hansard, MJ ;

Smith, LA ;

Jackson, MJ ;

Cheetham, SC ;

Jenner, P .

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2002, 303 (03) :952-958

[9] Dopamine reuptake inhibition and failure to evoke dyskinesia in MPTP-treated primates [J].

Hansard, MJ ;

Smith, LA ;

Jackson, MJ ;

Cheetham, SC ;

Jenner, P .

EUROPEAN JOURNAL OF PHARMACOLOGY, 2002, 451 (02) :157-160

[10] Sertraline for the treatment of depression in Parkinson's disease [J].

Hauser, RA ;

Zesiewicz, TA .

MOVEMENT DISORDERS, 1997, 12 (05) :756-759

← 1 2 →